153 related articles for article (PubMed ID: 32268796)
21. Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer.
Shaib WL; Narayan AS; Switchenko JM; Kane SR; Wu C; Akce M; Alese OB; Patel PR; Maithel SK; Sarmiento JM; Kooby DA; El-Rayes BF
Cancer; 2019 Jan; 125(1):57-67. PubMed ID: 30457666
[TBL] [Abstract][Full Text] [Related]
22. Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sueda T
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S646-55. PubMed ID: 22086444
[TBL] [Abstract][Full Text] [Related]
23. A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal disease.
Zou B; Xu Y; Li T; Li W; Tang B; Zhou L; Li L; Liu Y; Zhu J; Huang M; Wang J; Ren L; Gong Y; Che G; Liu L; Hou M; Lu Y
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):321-8. PubMed ID: 19775829
[TBL] [Abstract][Full Text] [Related]
24. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer.
Takahashi H; Ohigashi H; Ishikawa O; Gotoh K; Yamada T; Nagata S; Tomita Y; Eguchi H; Doki Y; Yano M
Ann Surg; 2012 Jan; 255(1):95-102. PubMed ID: 22123160
[TBL] [Abstract][Full Text] [Related]
25. S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
Okabayashi T; Shima Y; Iwata J; Morita S; Sumiyoshi T; Kozuki A; Tokumaru T; Iiyama T; Kosaki T; Kobayashi M; Hanazaki K
World J Surg; 2014 Nov; 38(11):2986-93. PubMed ID: 25104544
[TBL] [Abstract][Full Text] [Related]
26. Evidence-based guidelines for adjuvant therapy for resected adenocarcinoma of the pancreas.
Iott MJ; Corsini MM; Miller RC
Clin J Oncol Nurs; 2008 Aug; 12(4):599-605. PubMed ID: 18676327
[TBL] [Abstract][Full Text] [Related]
27. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
Hwang JE; Kim H; Shim HJ; Bae WK; Hwang EC; Jeong O; Ryu SY; Park YK; Cho SH; Chung IJ
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2157-2166. PubMed ID: 31273512
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant chemotherapy in elderly patients with pancreatic cancer.
Nagrial AM; Chang DK; Nguyen NQ; Johns AL; Chantrill LA; Humphris JL; Chin VT; Samra JS; Gill AJ; Pajic M; ; Pinese M; Colvin EK; Scarlett CJ; Chou A; Kench JG; Sutherland RL; Horvath LG; Biankin AV
Br J Cancer; 2014 Jan; 110(2):313-9. PubMed ID: 24263063
[TBL] [Abstract][Full Text] [Related]
29. [Effectiveness of adjuvant chemotherapy using gemcitabine for resected pancreatic cancer].
Suzuki S; Morishita K; Kaji S; Koike N; Harada N; Takeo Y; Hayashi T; Suzuki M; Hanyu F
Gan To Kagaku Ryoho; 2011 Jan; 38(1):65-8. PubMed ID: 21368460
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
[TBL] [Abstract][Full Text] [Related]
31. Postoperative gemcitabine alone and concurrent with radiation therapy in locally advanced pancreatic carcinoma.
Ozkok S; Demirci S; Yalman D; Zeytunlu M; Nart D; Yuzer Y; Coker A; Goker E
Tumori; 2010; 96(4):560-7. PubMed ID: 20968135
[TBL] [Abstract][Full Text] [Related]
32. Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial.
Abrams RA; Winter KA; Safran H; Goodman KA; Regine WF; Berger AC; Gillin MT; Philip PA; Lowy AM; Wu A; DiPetrillo TA; Corn BW; Seaward SA; Haddock MG; Song S; Jiang Y; Fisher BJ; Katz AW; Mehta S; Willett CG; Crane CH
Am J Clin Oncol; 2020 Mar; 43(3):173-179. PubMed ID: 31985516
[TBL] [Abstract][Full Text] [Related]
33. Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.
Oh SY; Kim HJ; Kim TH; Lee GW; Kim HG; Jeong CY; Kwon HC; Kang JH
Invest New Drugs; 2010 Jun; 28(3):343-9. PubMed ID: 19444385
[TBL] [Abstract][Full Text] [Related]
34. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Regine WF; Winter KA; Abrams RA; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Kudrimoti MR; Fromm ML; Haddock MG; Schaefer P; Willett CG; Rich TA
JAMA; 2008 Mar; 299(9):1019-26. PubMed ID: 18319412
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine.
Allen AM; Zalupski MM; Robertson JM; Eckhauser FE; Simone D; Brown D; Hejna G; Normolle D; Lawrence TS; McGinn CJ
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1461-7. PubMed ID: 15275733
[TBL] [Abstract][Full Text] [Related]
36. Survival effects of adjuvant gemcitabine plus S-1 chemotherapy on pancreatic carcinoma stratified by preoperative resectability status.
Murakami Y; Uemura K; Hashimoto Y; Kondo N; Nakagawa N; Takahashi S; Shintakuya R; Sueda T
J Surg Oncol; 2016 Mar; 113(4):405-12. PubMed ID: 26750513
[TBL] [Abstract][Full Text] [Related]
37. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment.
Petrillo A; Pappalardo A; Pompella L; Tirino G; Calabrese F; Laterza MM; Caterino M; Ventriglia A; Orditura M; Conzo G; Molino C; Ciardiello F; Biglietto M; De Vita F
Med Oncol; 2019 Aug; 36(10):83. PubMed ID: 31444639
[TBL] [Abstract][Full Text] [Related]
38. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R
Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
Berriochoa CA; Abdel-Wahab M; Leyrer CM; Khorana A; Matthew Walsh R; Kumar AMS
J Dig Dis; 2017 Nov; 18(11):642-649. PubMed ID: 29055078
[TBL] [Abstract][Full Text] [Related]
40. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
Schneitler S; Kröpil P; Riemer J; Antoch G; Knoefel WT; Häussinger D; Graf D
World J Gastroenterol; 2015 May; 21(20):6384-90. PubMed ID: 26034375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]